Latent membrane protein 2 (LMP2) (LMP2)

Latent membrane protein 2 (LMP2) is a viral protein encoded by the Epstein-Barr virus (EBV) that plays a critical role in maintaining viral latency and promoting oncogenesis (UniProt, Wikipedia). It exists in two isoforms, LMP2A and LMP2B, with LMP2A being the primary therapeutic target due to its consistent expression in EBV-associated malignancies such as nasopharyngeal carcinoma and Hodgkin lymphoma (PubMed, PMC). LMP2A functions as a B-cell receptor (BCR) mimic, providing constitutive survival signals to latently infected B cells while simultaneously blocking normal BCR signaling to prevent viral reactivation into the lytic cycle (UniProt, PubMed). This protein also interacts with host signaling pathways, including PI3K/Akt and mTOR, to promote cell proliferation and metabolic reprogramming in tumor cells (PMC). Because of its presence in tumor cells and its role in disease progression, LMP2 is a primary target for immunotherapeutic interventions, including therapeutic vaccines and adoptive T-cell therapies (PubMed, ResearchGate). Therapeutic strategies targeting LMP2 include recombinant viral vector vaccines like rAd5-EBV-LMP2 and MVA-LMP2A, as well as mRNA-based vaccines (PubMed, ResearchGate). Additionally, LMP2A's role in immune evasion, such as the downregulation of MHC class I and NKG2D ligands, makes it a target for combination therapies with immune checkpoint inhibitors like Pembrolizumab (PMC, ResearchGate).

Other names

Latent membrane protein 2ALMP2ALatent membrane protein 2BLMP2BTerminal protein 1TP1Terminal protein 2TP2EBV-associated membrane antigen

Antigen-specific immune activation, kinase inhibition (Syk, mTOR), and potentiation of immune checkpoint inhibition.